Avalon GloboCare Announces Publication Featuring QTY Code Technology in the Official Journal of the American Chemical Society
August 08, 2022 09:00 ET
|
Avalon GloboCare Corp.
Findings support utility of QTY protein code as a novel platform to generate water-soluble proteins for wide spectrum of biomedical applications Reports plans to apply for additional patents...
Avalon GloboCare Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer
June 30, 2022 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., June 30, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced a new...
Avalon GloboCare to Present at the Jefferies 2022 Healthcare Conference
May 25, 2022 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that David...
Avalon GloboCare Signs MOU to Form Strategic Partnership with Lu Daopei Hematology Institute to Develop Precision Companion Diagnostics for Cellular Therapy
May 18, 2022 09:00 ET
|
Avalon GloboCare Corp.
Goal of Partnership is to expand Avalon’s R&D pipeline to include innovative companion diagnostics in association with the company’s ongoing and future cellular immunotherapy clinical programs ...
Avalon GloboCare Expands IP Portfolio; Files 16 New Patent Applications
April 27, 2022 09:00 ET
|
Avalon GloboCare Corp.
Co-inventors are leading international universities and cellular therapy developers Patent applications cover three types of cellular therapies and related technologies FREEHOLD, N.J., April ...
Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies
February 14, 2022 09:00 ET
|
Avalon GloboCare Corp.
Leveraging Avalon’s existing Flash-CARTM technology platform to develop next-generation mRNA-based CAR-NK cellular therapeuticsClinical development of CAR-NK cell therapy planned in collaboration with...
Avalon GloboCare Provides Year-End Business Update of Selective Scientific and Clinical Programs
January 04, 2022 09:00 ET
|
Avalon GloboCare Corp.
Company continues to expand and accelerate its R&D strategies for high-impact translational and clinical programs in the US and Europe Intended SenlangBio acquisition terminated, eliminating...
Avalon GloboCare’s Chairman Converts Debt into Common Stock at 45% Premium to Market
December 22, 2021 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today...
Avalon GloboCare Advances AI-Enhanced Protein Design Technology for Cellular Therapy Development
December 09, 2021 09:00 ET
|
Avalon GloboCare Corp.
Avalon and research partner, Massachusetts Institute of Technology (MIT), combine their protein design “QTY Code” technology with Google’s DeepMind artificial intelligence (AI) program, AlphaFold2, to...
Avalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Drug Delivery and Cellular Immunotherapy
October 14, 2021 09:20 ET
|
Avalon GloboCare Corp.
Co-developed novel technology platform combining S-layer proteins and emulsomes for diverse applications in bio-delivery of drugs and genes with the University of Natural Resources and Life Sciences...